Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -317.74% | -129.26% | -76.29% | 24.87% | 49.97% |
| Total Depreciation and Amortization | -59.11% | 0.76% | -69.61% | -38.59% | -35.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,019.23% | 13.20% | -62.46% | 496.43% | 700.00% |
| Change in Net Operating Assets | 260,300.00% | -23.48% | 124.35% | -84.10% | -101.10% |
| Cash from Operations | -141.75% | -130.68% | -16.65% | 29.11% | 49.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.05% | 67.00% | 61.11% | 34.52% | -193.81% |
| Cash from Investing | 51.05% | 5.50% | -1.75% | 34.52% | -74.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.66% | 138.84% | -- | 194.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.66% | 138.84% | 100.00% | 194.67% | 30,728.57% |
| Foreign Exchange rate Adjustments | -281.20% | -172.73% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.49% | 162.15% | -8.14% | 3,569.22% | 318.18% |